Group
.webp&w=3840&q=90)
About the company
Pharmasyntez Group
One of Russia’s leading biopharmaceutical companies, operating across healthcare sectors including the research, development, manufacture and distribution of medicines of major public health importance, innovative medicines and active pharmaceutical ingredients
- 9
high-tech plants
- 29 years
of expertise
- 6,000
qualified employees
.webp&w=3840&q=90)
History
Our journey: key milestones and achievements
1997
Pharmasyntez was founded in Irkutsk. Construction of the first manufacturing site began.
1999
The first plant opened. Production of antibacterial, anti-tuberculosis and other medicines of major public health importance began.
2003–2005
East-Pharm was established, marking the start of our work in sterile dosage forms and infusion solutions.
2009–2010
The Irkutsk plant underwent extensive modernisation, and the second phase of its manufacturing facilities was commissioned.
2013
Production of antiretroviral medicines began. BratskChemSyntez was established to manufacture active pharmaceutical ingredients.
2015–2017
New manufacturing sites, Pharmasyntez-Tyumen and Pharmasyntez-Nord, were established, enabling the development of hormonal, anticancer and sterile medicine production.
2018–2020
API production capacity increased substantially. BratskChemSyntez launched its first unit for large-scale production of pharmaceutical ingredients. Vladimir Putin, President of the Russian Federation, attended the opening of the manufacturing complex online.
2021
The first in-house R&D centre opened. The company began actively developing its biotechnology operations and manufacturing biotechnology medicines.
2022–2023
The second Pharmasyntez-Nord manufacturing site was commissioned. Vladimir Putin, President of the Russian Federation, attended the opening ceremony. Capacity for anticancer and biotechnology medicines expanded, recombinant insulin production was established, and exports to overseas markets began.
2024
A modern R&D centre opened in Tyumen, production of new medicines began, and GMP certification was obtained from the Brazilian regulator ANVISA, opening up new export opportunities.
2025
The Dzhinatek plant opened, research infrastructure expanded, and registration began for an innovative medicine developed in Russia for the treatment of chronic myeloid leukaemia.
2026
Construction began on the third Pharmasyntez-Nord manufacturing site and a new R&D centre to expand monoclonal antibody production and advance biotechnology research.
Opening of the second phase of the East-Pharm plant for the production of injectable dosage forms
Careers
Work that makes a real difference to millions
Support for professional growth, opportunities to fulfil your potential and a comfortable working environment provide a foundation for confident progress at every stage of your career.
News
